MBX Biosciences, Inc. (MBX) Stock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.

In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.